Personalized Medicine Will Lead To Changes In FDA Approval Process For New Medications, Von Eschenbach Says

November 13, 2008

Personalized medicine — the ability to predict how patients will react to certain medications based on their genetic profiles — will lead to changes in clinical trials and the business model for the pharmaceutical industry, as well as the FDA approval process for new treatments, agency commissioner Andrew von Eschenbach said on Friday during a speech to business students at St. Joseph’s University, the Philadelphia Inquirer reports. (Medical News Today)